Gyre Therapeutics (GYRE) Short Interest Ratio & Short Volume → Trump’s last act as President (From Porter & Company) (Ad) Free GYRE Stock Alerts $13.86 -1.74 (-11.15%) (As of 05/1/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Gyre Therapeutics Short Interest DataCurrent Short Volume181,900 sharesPrevious Short Volume121,200 sharesChange Vs. Previous Month+50.08%Dollar Volume Sold Short$3.00 millionShort Interest Ratio / Days to Cover2.3Last Record DateApril 15, 2024Outstanding Shares85,470,000 sharesFloat Size13,940,000 sharesShort Percent of Float1.30%Today's Trading Volume125,154 sharesAverage Trading Volume74,759 sharesToday's Volume Vs. Average167% Short Selling Gyre Therapeutics ? Sign up to receive the latest short interest report for Gyre Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatGYRE Short Interest Over TimeGYRE Days to Cover Over TimeGYRE Percentage of Float Shorted Over Time Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him Gyre Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/2024181,900 shares $3.00 million +50.1%1.3%2.3 $16.48 3/31/2024121,200 shares $2.12 million -3.2%0.9%1.5 $17.48 3/15/2024125,200 shares $2.10 million -10.4%1.0%1.5 $16.76 2/29/2024139,700 shares $2.53 million -10.6%1.1%1.4 $18.14 2/15/2024156,300 shares $2.50 million -25.6%1.3%1.3 $15.97 1/31/2024210,000 shares $2.60 million No Change1.7%1.8 $12.37 GYRE Short Interest - Frequently Asked Questions What is Gyre Therapeutics' current short interest? Short interest is the volume of Gyre Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 181,900 shares of GYRE short. 1.30% of Gyre Therapeutics' shares are currently sold short. Learn More on Gyre Therapeutics' current short interest. What is a good short interest ratio for Gyre Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GYRE shares currently have a short interest ratio of 2.0. Learn More on Gyre Therapeutics's short interest ratio. What is a good short interest percentage for Gyre Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.30% of Gyre Therapeutics' floating shares are currently sold short. Is Gyre Therapeutics' short interest increasing or decreasing? Gyre Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 181,900 shares, an increase of 50.1% from the previous total of 121,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Gyre Therapeutics' float size? Gyre Therapeutics currently has issued a total of 85,470,000 shares. Some of Gyre Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Gyre Therapeutics currently has a public float of 13,940,000 shares. How does Gyre Therapeutics' short interest compare to its competitors? 1.30% of Gyre Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Gyre Therapeutics: ANI Pharmaceuticals, Inc. (1.01%), Morphic Holding, Inc. (12.48%), Akero Therapeutics, Inc. (11.83%), Arcus Biosciences, Inc. (14.45%), Day One Biopharmaceuticals, Inc. (15.17%), Kura Oncology, Inc. (15.93%), Ironwood Pharmaceuticals, Inc. (13.96%), Kiniksa Pharmaceuticals, Ltd. (5.16%), Ligand Pharmaceuticals Incorporated (4.98%), Dynavax Technologies Co. (14.17%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Gyre Therapeutics stock? Short selling GYRE is an investing strategy that aims to generate trading profit from Gyre Therapeutics as its price is falling. GYRE shares are trading down $1.74 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Gyre Therapeutics? A short squeeze for Gyre Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GYRE, which in turn drives the price of the stock up even further. How often is Gyre Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GYRE, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: ANI Pharmaceuticals Short Squeeze Morphic Short Squeeze Akero Therapeutics Short Squeeze Arcus Biosciences Short Squeeze Day One Biopharmaceuticals Short Squeeze Kura Oncology Short Squeeze Ironwood Pharmaceuticals Short Squeeze Kiniksa Pharmaceuticals Short Squeeze Ligand Pharmaceuticals Short Squeeze Dynavax Technologies Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GYRE) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubDollar CancelledLear CapitalUrgent Alert: Is the U.S. Implementing a Digital Dollar?Gold Gate Capital